Federal Supply Schedule (FSS) Pricing Added to ProspectoRx From Elsevier / Gold Standard

By Elsevier, PRNE
Wednesday, March 2, 2011

Addition Creates a More Comprehensive Pricing and Analytics Tool for Pharmaceutical Companies, Pharmacy Benefits Managers and Pharmacy Headquarters

TAMPA, Florida, March 3, 2011 - Elsevier / Gold Standard (www.goldstandard.com/index.html), a
leading developer of drug databases and medication management solutions,
announced today several enhancements to its pricing tool, ProspectoRx (
including the addition of Federal Supply Schedule (FSS) pricing to facilitate
pricing analysis.

The rate and frequency at which drug prices change in today's
competitive environment make current, accurate and easily accessible pricing
information critical to success in the pharmaceutical industry. The addition
of FSS pricing for analysis makes ProspectoRx an even more comprehensive
pricing and analytics tool by providing immediate access to competitive
federal pricing, better marketplace knowledge and less time spent

"As the only real-time pricing tool available, our customers
rely on ProspectoRx for current and accurate information," stated Kay Morgan,
SVP, Drug Products and Industry Standards for Elsevier / Gold Standard. "Our
customers requested to make their analysis of markets and pricing faster and
easier, so the addition of FSS will further aid them with the pricing
analysis they need to make decisions and form the right strategies."

Derived from Elsevier / Gold Standard's Alchemy
(www.goldstandard.com/pages/alchemy.html?epm=1_1) drug product and
pricing files, ProspectoRx includes extensive information on brand and
generic drugs, delivering immediate access to price changes and new product
information. It already includes extensive pricing information, including:
reported Average Wholesale Price (AWP), Wholesale Acquisition Cost (WAC),
Direct Price (DP), and Federal Upper Limit (CMS-FUL), as well as Calculated
Average Wholesale Price (C-AWP) 1.20 and 1.25, and Calculated Federal Upper
Limit (C-CMS-FUL).

Other enhancements include multiple watch lists and enhanced
price change notifications, a new label name search box for market class,
along with an improved interface, help tab, and report download capabilities.

For more information on how to stay current on drug prices,
contact Elsevier / Gold Standard at goldstandard@elsevier.com or

About Elsevier / Gold Standard

Based in Tampa, FL, Elsevier / Gold Standard uses innovative
technologies to provide a complete suite of drug information and decision
support solutions. With a tenacious commitment to product quality, Elsevier /
Gold Standard solutions empower healthcare organizations, professionals and
consumers to meet the most pressing healthcare challenges, improve patient
safety and ensure optimal outcomes. To learn more about Elsevier / Gold
Standard, visit www.goldstandard.com.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. The company works in partnership
with the global science and health communities to publish more than 2,000
journals, including The Lancet (www.thelancet.com) and Cell
(www.cell.com), and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier's online solutions include
SciVerse ScienceDirect (www.sciencedirect.com), SciVerse Scopus
(www.scopus.com), Reaxys (www.reaxys.com), MD Consult
(www.mdconsult.com) and Nursing Consult (www.nursingconsult.com
), which enhance the productivity of science and health professionals, and
the SciVal suite (www.scival.com) and MEDai's Pinpoint Review
(www.medai.com), which help research and health care institutions
deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (
www.elsevier.com) employs 7,000 people worldwide. The company is part
of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading
publisher and information provider, which is jointly owned by Reed Elsevier
PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam),
REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

    Media Contact

    Tom Reller

Media Contact: Tom Reller, +1-212-462-1912, T.Reller at Elsevier.com

will not be displayed